Given that GCN2 activation requires an association with a heterodimer consisting of GCN1 and GCN20 (ABCF3), it could be hypothesised that changes in these proteins would likely impact on the ability of GCN2 to act as either tumour suppressor or oncogene. This evidence concerns the gene EIF2AK4 and neoplasm.